Acetaminophen combinations protect against iron-induced cardiac damage in gerbils

Annals of Clinical and Laboratory Science

Volumn 39, Issue 4, 2009, Pages 378-385

  Walker Jr , Ernest M ^a   Morrison, Ryan G ^b   Dornon, Lucy ^a   Laurino, Joseph P ^c   Walker, Sandra M ^a   Studeny, Mark ^a,d   Wehner, Paulette S ^a,d   Rice, Kevin M ^a   Wu, Miaozong ^a   Blough, Eric R ^a  

^a MARSHALL UNIVERSITY   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TAMPA   (United States)

^d St Mary's Medical Center Huntington   (United States)

Author keywords

Acetaminophen; Deferoxamine; Iron overload; N methyl D glucamine dithiocarbamate

Indexed keywords

DEFEROXAMINE; DEXTRAN; FERRIC HYDROXIDE; IRON; N METHYLGLUCAMINE N CARBODITHIOIC ACID; PARACETAMOL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CONTROLLED STUDY; DRUG EFFICACY; ELECTROCARDIOGRAPHY; GERBIL; HEART ARRHYTHMIA; HEART FUNCTION; HEART INJURY; HEART PROTECTION; HEART WEIGHT; INCIDENCE; IRON OVERLOAD; LIVER LEVEL; LIVER WEIGHT; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL;

ACETAMINOPHEN; ANIMALS; ARRHYTHMIAS, CARDIAC; BODY WEIGHT; CARDIOTONIC AGENTS; ELECTROCARDIOGRAPHY; GERBILLINAE; HEART FUNCTION TESTS; IRON; LIVER; MALE; MYOCARDIUM; ORGAN SIZE;

GERBILLINAE;

EID: 73349108069     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Walker EM Jr, Wolfe MD, Norton ML, Jones MM. Hereditary hemochromatosis. Ann Clin Lab Sci 1998;28:300-312.
2. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.
3. Bothwell TH, MacPhail AP. Hereditary hemochromatosis: etiologic, pathologic, and clinical aspects. Semin Hematol 1998;35:55-71.
4. Brandhagen DJ, Fairbanks VF, Baldus W. Recognition and management of hereditary hemochromatosis. Am Fam Physician 2002;65:853-860.
5. Kontoghiorghes GJ, Pattichi K, Hadjigavriel M, Kolnagou A. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). Transfus Sci 2000; 23:211-223.
6. Nichols GM, Bacon BR. Hereditary hemochromatosis: pathogenesis and clinical features of a common disease. Am J Gastroenterol 1989;84:851-862.
7. Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-1190.
8. Merson L, Olivier N. Orally active iron chelators. Blood Rev 2002;16:127-134.
9. Choudhry VP, Pati HP, Saxena A, Malariva AN. Deferiprone: efficacy and safety. Indian J Pediatr 2004; 71:213-216.
10. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator in patients with β-thalassemia. Blood 2006;107:3455-3462.
11. Cappellini MD. Iron-chelating therapy with the new oral agent ICL 670 (Exjade® ). Best Pract Res Clin Haematol 2005;18:289-98.
12. Walker EM Jr, Epling CP, Parris C, Cansino S, Ghosh P, Desai DH, Morrison RG, Wright GL,Wehner P, Mangiarua EI, Walker SM, Blough ER. Acetaminophen protects against iron-induced cardiac damage in gerbils. Ann Clin Lab Sci 2007; 37:22-33.
13. Walker EM Jr. Method of treating iron overload with acetaminophen. US Patent #6,509,380; 2002. Marshall University, Huntington, WV 25704.
14. Otto CM. Principles of echocardiographic image acquisition and Doppler analysis. In: Textbook of Clinical Echocardiography (Otto, CM, Ed), Saunders, Philadelphia, 2000; pp 1-28.
15. Manning TJ, Grow WR. Inductively coupled plasma-atomic emission spectrometry. In: The Chemical Educator, Springer-Verlag, New York, 1997;2:1-19.
16. Ellerton S-Y, Stacey MC. Iron and 8-isoprostane levels in acute and chronic wounds. J Invest Dermatol 2003; 121:918-925.
17. Schwartz KA, Zy L, Schwartz DE, Cooper TG, Braselton WE. Earliest cardiac toxicity induced by iron overload selectively inhibits electrical conduction. J Appl Physiol 2002;93:746-751.
18. van de Wiel HJ. Determination of Elements by ICP-AES and ICP-MS. National Institute of Public Health and the Environment (RIVM). Bilthoven, The Netherlands. 2003; pp 1-19.
19. Walker EM Jr, Fazekas-May MA, Heard KW, Kleve MG, Good BH, Montague D, Jones MM. Amelioration of cisplatin-induced ototoxicity and nephrotoxicity by diethyldithio-carbamate (DDTC) and analogs. Ann Clin Lab Sci 1994;24: 121-133.
20. Walker EM Jr, Shah D, Cannon DJ, Larsen B, Jones MM. Comparative iron mobilizing actions of selected chelating agents in iron-loaded mice. Ann Clin Lab Sci 1994;24:478.
21. Lai CS. Methods for in vivo reduction of iron levels and compositions useful therefor. U.S. Patent # 5,922,761, July 13, 1999; (Medinox, Inc., San Diego, CA).
22. Thomas BH, Nera EA, Zeitz W. Failure to observe pathology in the rat following chronic dosing with acetaminophen and acetylsalicylic acid. Res Commun Chem Path Pharmacol 1977;17:663-678.
23. Jeong SY, Llim JS, Park HJ, Cho JW, Rana SV, Yoon S. Effects of acetaminophen on hepatic gene expression in mice. Physiol Chem Phys Med NMR 2006;38:77-83.
24. Schellhammer P, Engle M, Hagstrom J. Histochemical studies of the myocardium and conduction system in acquired iron-storage disease. Circulation 1967;35:631-637.
25. Fitchett D, Coltart D, Littler W, Leyland MJ, Trueman T, Gozzard D, Peters T. Cardiac involvement in secondary hemochromatosis. Cardiovasc Res 1980;14:7199-7284.
26. Sanyal S, Johnson W, Jayalakshamma B, Green A. Fatal "iron heart" in an adolescent: biochemical and ultrastructural aspects of the heart. Pediatrics 1975;55:336-341.
27. Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 1994;8:101-110.
28. Buja L, Roberts W. Iron in the heart. Am J Med 1971;51:209-221.
29. Olson LJ, Edwards WD, McCall JT, Ilstup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: Histologic and analytic assessment of 14 hearts from autopsy. J Am Coll Cardiol 1987;10:1239-1243.
30. Rahko P, Salerni R, Uretsky B. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol 1986;8:436-440.
31. Leon M, Borer J, Bacharach S, Green M, Benz E, Griffith P, and Nienhuis A. Detection of early cardiac dysfunction in patients with severe beta-thalassemia and chronic iron overload. NEJM 1979;301:1143-1148.
32. Wolfe L, Olivieri N, Sallan D, Colan, S, Rose V, Propper R, Freedman M, Nathan D. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. NEJM 1985;312:1600-1603.
33. Koren A, Garty I, Antonelli D, Katzuni E. Right ventricular cardiac dysfunction in beta-thalassemia major. Am J Dis Child 1987;141:93-96.
34. Link G, Pinson A, Hershko C . Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 1985;106:147-153.
35. Walker JM. The heart in thalassemia. Eur Heart 2002;23:102-105.
36. Brittenham GM, Griffith PM, Nienhuis AW, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. NEJM 1994;331:567-573.